Immunotherapy
Cancer treatment that trains the patient's own immune system to attack tumors.
Coverage of Immunotherapy is holding steady : 13 signals on the latest tracked day, level with its three-week baseline of 13, across 4 domains (down from 9 a week ago). That makes it the #94 most-covered of the 337 concerns we track.
What’s changed
6 of the last 7 tracked days ran above the three-week baseline — a sustained move, not a one-day spike.
- A first-in-human, phase I/IIa trial of the T cell immunotherapy personalised tumour trained lymphocytes in patients with advanced colorectal cancer · PLOS ONE · 2026-09-20
- Tumor mutational burden studied as prognostic marker in metastatic CRC receiving immunotherapy · crc-digest · 2026-09-19
- Gut microbiome may influence resistance to immunotherapy in MSI-H/dMMR colorectal cancer · crc-digest · 2026-09-19
- Chemoradiotherapy plus immunotherapy may expand checkpoint blockade benefit in mismatch repair-proficient rectal cancer · crc-digest · 2026-09-18
- Beyond the barrier: Engineering the tumor-immune-soil nexus-a mechanistic blueprint for integrating Traditional Chinese Medicine with immunotherapy in metastatic colorectal cancer. · Med Oncol · 2026-09-15
- Targeting intracellular immune regulatory molecules for cancer immunotherapy in solid tumors. · Crit Rev Oncol Hematol · 2026-09-13
What the reporting says
It shows up alongside Colorectal Cancer (232), Lung Cancer (64), MSI-H (54), Overall Survival (69), KRAS (31), T Cell (43), FDA (54), AI (43).
Two steps out: ctDNA (through Colorectal Cancer, 122 shared stories on the weaker link); Braf (through Colorectal Cancer, 86 shared stories on the weaker link); Wang (through Colorectal Cancer, 71 shared stories on the weaker link); Egfr (through Colorectal Cancer, 63 shared stories on the weaker link).
Tracked since Jan 1, with coverage on 123 separate days — concentrated in Oncology and Pubmed Targeted.